According to our new research study on "Embolization Coils Market Forecast to 2031 - Global Analysis - by Coils, Application, End User, and Geography," the market is expected to grow from US$ 1,877.12 million in 2024 to US$ 3,685.07 million by 2031; it is estimated to record a CAGR of 10.2% from 2025-2031. Key factors driving the growth of the embolization coils market are the rising prevalence of vascular disorders and aneurysms, burgeoning demand for minimally invasive procedures, and an aging population.

The scope of the embolization coils market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. Asia Pacific is anticipated to register the fastest CAGR in the embolization coils market from 2025 to 2031. The Asia Pacific countries are experiencing a rise in the occurrences of such diseases as cerebral aneurysms, hepatocellular carcinoma, and peripheral vascular diseases. These diseases are primary sources for minimally invasive embolization procedures. Technology innovations-like softer, more trackable coils and improved delivery systems-are making the procedures safer and more effective, thus increasing their use clinically, thereby supporting the embolization coils market growth in the Asia Pacific.

Patient and doctor preferences are changing towards minimally invasive methods as a result of the advantages of shorter hospital stays, fewer complications, and quicker recovery. Moreover, cost-effective local manufacturers in China and India are improving both the availability and the affordability of products, thus facilitating the penetration of embolization coils, accelerating the growth of the Asia-Pacific embolization coils market in the near future.

China has been a major contributor to the global burden of peripheral artery disease (PAD). The Journal of Vascular Surgery published a study showing that in China, the number of people living with PAD increased by nearly 40% in the period 2000 to 2020. Moreover, the high rate of occurrence is further enhanced by the enormous population and aging trend of the country, with epidemiological studies verifying that UIAs are a significant public health issue where rupture dangers increase with the likes of hypertension and smoking, which are common in urban areas.

Embolization coils are usually inserted in endovascular coiling operations to close cerebral aneurysms, as illustrated in the China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA), which showed less rupture incidence after the intervention. The most recent changes entail the 2024 endorsement of Endovastec's Cratos Branched Aortic Stent Graft System, which helps in the accurate embolization of complex vascular anomalies, and, at the same time, there are improvements in bioactive coils that lead to quicker thrombosis, thus becoming a significant factor aiding the embolization coils market in the region.

Zylox-Tonbridge's ZYLOX Phoenix Peripheral Detachable Fibered Coil Embolization System was granted marketing approval by the National Medical Products Administration (NMPA) in January 2024. MicroPort NeuroTech (Shanghai) Co., Ltd., received the US FDA approval for the NUMEN Silk Coil Embolization System (NUMEN Silk) in October 2024, marking its entry into the US market, its second international market after China.

In December 2023, MicroPort NeuroTech made the announcement that the NUMEN Coil Embolization System successfully completed the first batch of clinical implantations on October 10 in Japan. After the announcement, within three weeks, 28 operations were performed successfully in 22 hospitals in Japan with a positive response, overall. Moreover, in October, Japan's Ministry of Health, Labour and Welfare (MHLW) accorded NUMEN approval for its inclusion in public medical insurance, further fueling the growth of the embolization coils market.

The increasing demand for embolization coils is mainly due to India's demographic explosion - 1.4 billion people with a 10% annual increase in vascular diseases. The occurrence of cancer and stroke is increasing due to lifestyle changes; the government-backed Ayushman Bharat scheme that provides insurance to 500 million people for endovascular procedures; and rapid urbanization, which is expanding the cath lab network to 2,000 by 2025.

Importation of technology and training programs is making the minimally invasive methods more accessible to a larger number of people, thus addressing the problem of late diagnoses and creating opportunities for coil therapies for aneurysms and tumors. As a result, the region is becoming a new center of affordable neurointerventional care, thereby bolstering the embolization coils market growth. Therefore, the factors mentioned above are promoting a favorable environment for the embolization coils market in the region.

NeuroSafe Medical Co. Ltd., Stryker Corp., Cook Medical Holdings LLC, Medtronic Plc, Terumo Corp., Boston Scientific Corp., Wallaby Medical, Penumbra Inc., Balt, and INVAMED are among the leading companies profiled in the embolization coils market report.

Based on coils, the embolization coils market is divided into central application and peripheral application. By application, the market is segmented into neurology, peripheral vascular disease, oncology, urology, and others. In terms of end user, the embolization coils market is classified into hospitals, ambulatory centers, and others. Geographically, the embolization coils market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com